The future of patient-derived tumor xenografts in cancer treatment

Pharmacogenomics

Volumn 16, Issue 14, 2015, Pages 1671-1683

  Sia, Daniela ^a,b,c   Moeini, Agrin ^a,c   Labgaa, Ismail ^c   Villanueva, Augusto ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

avatar; biomarkers; co clinical trials; mouse models; personalized medicine

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; COLORECTAL CANCER; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; EXPERIMENTAL MODEL; GENETIC HETEROGENEITY; HUMAN; IMMUNOCOMPROMISED PATIENT; MOLECULAR GENETICS; MOLECULAR STABILITY; NONHUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; REVIEW; STUDY DESIGN; TISSUE ENGINEERING; TRANSLATIONAL RESEARCH; TUMOR ENGRAFTMENT; TUMOR INITIATING CELL; TUMOR XENOGRAFT; XENOTRANSPLANTATION; ANIMAL; CANCER TRANSPLANTATION; MOUSE; XENOGRAFT;

ANIMALS; BIOMARKERS, TUMOR; HETEROGRAFTS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PRECISION MEDICINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945565935     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.102     Document Type: Review

References (103)

1. Pharmaceutical Research and Manufacturers of America. www.phrma.org Challenges and Opportunities Report-March 2004. U.S. Department of Health and Human Services. Food and Drug Administration. www.fda.gov/ScienceResearch/SpecialTopics/
2. Gan HK, You B, Pond GR et al. Assumptions of expected benefts in randomized Phase III trials evaluating systemic treatments for cancer. J. Natl Cancer Inst. 104(8), 590-598 (2012).
3. Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 74(9), 2377-2384 (2014).
4. Johnson JI, Decker S, Zaharevitz D et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84(10), 1424-1431 (2001).
5. Daniel VC, Marchionni L, Hierman JS et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69(8), 3364-3373 (2009).
6. Tveit KM, Pihl A. Do cell lines in vitro refect the properties of the tumours of origin? A study of lines derived from human melanoma xenografts. Br. J. Cancer 44(6), 775-86 (1981).
7. Alsinet C, Cornella H, Villanueva A. Genetically engineered mouse models: future tools to predict clinical trial results in oncology? Future Oncol. 9(6), 767-70 (2013).
8. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66(7), 3351-3354, discussion 3354 (2006).
9. Singh M, Ferrara N. Modeling and predicting clinical effcacy for drugs targeting the tumor milieu. Nat. Biotechnol. 30(7), 648-657 (2012).
10. Kameya T, Shimosato Y, Tumuraya M et al. Human gastric choriocarcinoma serially transplanted in nude mice. J. Natl Cancer Inst. 56(2), 325-332 (1976).
11. Shimosato Y, Kameya T, Nagai K et al. Transplantation of human tumors in nude mice. J. Natl Cancer Inst. 56(6), 1251-1260 (1976).
12. Tentler JJ, Tan AC, Weekes CD et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9(6), 338-350 (2012).
13. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodefcient mice. Nat. Protoc. 2(2), 247-250 (2007).
14. Jin K, Teng L, Shen Y et al. Patient-derived human tumour tissue xenografts in immunodefcient mice: a systematic review. Clin. Transl. Oncol. 12(7), 473-480 (2010).
15. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73(17), 5315-5319 (2013).
16. Cutz JC, Guan J, Bayani J et al. Establishment in severe combined immunodefciency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin. Cancer Res. 12(13), 4043-4054 (2006).
17. Lee CH, Xue H, Sutcliffe M et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol. Oncol. 96(1), 48-55 (2005).
18. Wang Y, Revelo MP, Sudilovsky D et al. Development and characterization of effcient xenograft models for benign and malignant human prostate tissue. Prostate 64(2), 149-159 (2005).
19. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin. Pharmacol. Ther. 85(2), 217-221 (2009).
20. Xia TS, Wang J, Yin H et al. Human tissue-specifc microenvironment: an essential requirement for mouse models of breast cancer. Oncol. Rep. 24(1), 203-211 (2010).
21. Wilmanns C, Fan D, Obrian C et al. Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice. Int. J. Oncol. 3(3), 413-422 (1993).
22. Lock RB, Liem N, Farnsworth ML et al. The nonobese diabetic/severe combined immunodefcient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99(11), 4100-4108 (2002).
23. Baccelli I, Schneeweiss A, Riethdorf S et al. Identifcation of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31(6), 539-544 (2013).
24. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifes HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1(6), 508-523 (2011).
25. Bogachek MV, Park JM, De Andrade JP et al. A novel animal model for locally advanced breast cancer. Ann. Surg. Oncol. 22(3), 866-873 (2015).
26. Mohseni MJ, Amanpour S, Muhammadnejad S et al. Establishment of a patient-derived Wilms' tumor xenograft model: a promising tool for individualized cancer therapy. J. Pediatr. Urol. 10(1), 123-129 (2014).
27. Zhang H, Cohen AL, Krishnakumar S et al. Pat ient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 16(2), R36 (2014).
28. Zhao X, Liu Z, Yu L et al. Global gene expression profling confrms the molecular fdelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro. Oncol. 14(5), 574-583 (2012).
29. de Plater L, Lauge A, Guyader C et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br. J. Cancer 103(8), 1192-200 (2010).
30. Fichtner I, Rolff J, Soong R et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identifcation of predictive biomarkers. Clin. Cancer Res. 14(20), 6456-6468 (2008).
31. Karam JA, Zhang XY, Tamboli P et al. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur. Urol. 59(4), 619-628 (2011).
32. Merk J, Rolff J, Becker M et al. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur. J. Cardiothorac. Surg. 36(3), 454-459 (2009).
33. Rubio-Viqueira B, Jimeno A, Cusatis G et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12(15), 4652-4661 (2006).
34. Terziyska N, Castro Alves C, Groiss V et al. In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. PLoS ONE 7(12), e52798 (2012).
35. Uronis JM, Osada T, McCall S et al. Histological and molecular evaluation of patient-derived colorectal cancer explants. PLoS ONE 7(6), e38422 (2012).
36. Dangles-Marie V, Pocard M, Richon S et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 67(1), 398-407 (2007).
37. Bogner PN, Patnaik SK, Pitoniak R et al. Lung cancer xenografting alters microRNA profle but not immunophenotype. Biochem. Biophys. Res. Commun. 386(2), 305-310 (2009).
38. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010).
39. Reyal F, Guyader C, Decraene C et al. Molecular profling of patient-derived breast cancer xenografts. Breast Cancer Res. 14(1), R11 (2012).
40. Hidalgo M, Amant F, Biankin AV et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4(9), 998-1013 (2014).
41. Garrido-Laguna I, Uson M, Rajeshkumar NV et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17(17), 5793-5800 (2011).
42. Raheem O, Kulidjian AA, Wu C et al. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J. Transl. Med. 9, 185 (2011).
43. Loukopoulos P, Kanetaka K, Takamura M et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity Pancreas 29(3), 193-203 (2004).
44. Ishikawa F, Yasukawa M, Lyons B et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106(5), 1565-1573 (2005).
45. Joo SY, Chung YS, Choi B et al. Systemic human T cell developmental processes in humanized mice cotransplanted with human fetal thymus/liver tissue and hematopoietic stem cells. Transplantation 94(11), 1095-1102 (2012).
46. Talmadge JE, Singh RK, Fidler IJ et al. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 170(3), 793-804 (2007).
47. Bankert RB, Balu-Iyer SV, Odunsi K et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE 6(9), e24420 (2011).
48. Shultz LD, Brehm MA, Garcia-Martinez JV et al. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12(11), 786-798 (2012).
49. Brehm MA, Shultz LD, Luban J et al. Overcoming current limitations in humanized mouse research. J. Infect. Dis. 208(Suppl. 2), S125-S130 (2013).
50. The Breast Cancer Genome-Guided Therapy (BEAUTY) study. Mayo Clinic Cancer Center. http://mayoresearch.mayo.edu/
51. HERACLES study. Istituto di Candiolo. www.ircc.it/irccit/?q = Heracles-Trial
52. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104(24), 10158-10163 (2007).
53. Fiebig HH, Schuler J, Bausch N et al. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics 4(3), 197-209 (2007).
54. Hammers HJ, Verheul HM, Salumbides B et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol. Cancer Ther. 9 (6), 1525-1535 (2010).
55. Jin K, Lan H, Cao F et al. Differential response to EGFR-and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Int. J. Oncol. 41(2), 583-588 (2012).
56. Jin K, Li G, Cui B et al. Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS ONE 6(12), e28384 (2011).
57. Kabos P, Finlay-Schultz J, Li C et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help defne unique estrogen-dependent gene signatures. Breast Cancer Res. Treat. 135(2), 415-432 (2012).
58. Keysar SB, Le PN, Anderson RT et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 73(11), 3381-3392 (2013).
59. Kortmann U, McAlpine JN, Xue H et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. 17(4), 783-791 (2011).
60. Moestue SA, Borgan E, Huuse EM et al. Distinct choline metabolic profles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 10, 433 (2010).
61. Nemati F, Sastre-Garau X, Laurent C et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin. Cancer Res. 16(8), 2352-2362 (2010).
62. Oudard S, Legrier ME, Boye K et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J. Urol. 169(5), 1729-1734 (2003).
63. Romanelli A, Clark A, Assayag F et al. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Mol. Cancer Ther. 11(12), 2693-2703 (2012).
64. Schatton T, Murphy GF, Frank NY et al. Identifcation of cells initiating human melanomas. Nature 451(7176), 345-349 (2008).
65. Seguin L, Kato S, Franovic A et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 16(5), 457-468 (2014).
66. Serra V, Eichhorn PJ, Garcia-Garcia C et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J. Clin. Invest. 123(6), 2551-2563 (2013).
67. Tentler JJ, Nallapareddy S, Tan AC et al. Identifcation of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol. Cancer Ther. 9(12), 3351-3362 (2010).
68. Venkatesha VA, Parsels LA, Parsels JD et al. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 14(6), 519-525 (2012).
69. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369 (18), 1691-1703 (2013).
70. Wu X, Zhang J, Zhen R et al. Trastuzumab anti-tumor effcacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J. Transl. Med. 10, 180 (2012).
71. Yuen JS, Sim MY, Siml HG et al. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br. J. Cancer 104(6), 941-947 (2011).
72. Zhang J, Zhang L, Su X et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplifed non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin. Cancer Res. 18(24), 6658-6667 (2012).
73. DeRose YS, Wang G, Lin YC et al. Tumor grafts derived from women with breast cancer authentically refect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17(11), 1514-1520 (2011).
74. Sivanand S, Pena-Llopis S, Zhao H et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 4(137), 137ra75 (2012).
75. Kleine W. Prognostic signifcance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice. Gynecol. Oncol. 25(1), 65-72 (1986).
76. Rajeshkumar NV, Tan AC, De Oliveira E et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 15 (12), 4138-4146 (2009).
77. Liem NL, Papa RA, Milross CG et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103(10), 3905-3914 (2004).
78. Carol H, Szymanska B, Evans K et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin. Cancer Res. 19(7), 1795-1805 (2013).
79. Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J. Clin. Oncol. 29(34), 4548-4554 (2011).
80. Ong FS, Das K, Wang J et al. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev. Mol. Diagn. 12(6), 593-602 (2012).
81. de Mello RA, Madureira P, Carvalho LS et al. EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics 14(14), 1765-1777 (2013).
82. Flaherty K T, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
83. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31(15), 1806-1814 (2013).
84. Herter-Sprie GS, Kung AL, Wong KK. New cast for a new era: preclinical cancer drug development revisited. J. Clin. Invest. 123(9), 3639-3645 (2013).
85. Lunardi A, Pandolf PP. A co-clinical platform to accelerate cancer treatment optimization. Trends Mol. Med. 21(1), 1-5 (2015).
86. Nardella C, Lunardi A, Patnaik A et al. The APL paradigm and the "co-clinical trial" project. Cancer Discov. 1(2), 108-116 (2011).
87. Chen Z, Cheng K, Walton Z et al. A murine lung cancer co-clinical trial identifes genetic modifers of therapeutic response. Nature 483(7391), 613-617 (2012).
88. Lunardi A, Ala U, Epping MT et al. A co-clinical approach identifes mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat. Genet. 45 (7), 747-755 (2013).
89. Dong X, Guan J, English JC et al. Patient-derived frst generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 16 (5), 1442-1451 (2010).
90. Garrido-Laguna I, Tan AC, Uson M et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br. J. Cancer 103(5), 649-655 (2010).
91. Jimeno A, Amador ML, Kulesza P et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol. Cancer Ther. 5(12), 3240-3247 (2006).
92. Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 344(1), 1-12 (2014).
93. Roper J, Hung KE. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol. Sci. 33(8), 449-455 (2012).
94. Hidalgo M, Bruckheimer E, Rajeshkumar NV et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10(8), 1311-1316 (2011).
95. Clohessy JG, Pandolf PP. Mouse hospital and co-clinical trial project-from bench to bedside. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.62 (2015) (Epub ahead of print).
96. Julien S, Merino-Trigo A, Lacroix L et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18(19), 5314-5328 (2012).
97. Moestue SA, Huuse EM, Lindholm EM et al. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. J. Magn. Reson. Imaging 38(5), 1043-1053 (2013).
98. Streeter JE, Herrera-Loeza SG, Neel NF et al. A comparative evaluation of ultrasound molecular imaging, perfusion imaging, and volume measurements in evaluating response to therapy in patient-derived xenografts. Technol. Cancer Res. Treat. 12(4), 311-21 (2013).
99. Moestue SA, Dam CG, Gorad SS et al. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res. 15(1), R16 (2013).
100. Kalscheuer H, Danzl N, Onoe T et al. A model for personalized in vivo analysis of human immune responsiveness. Sci. Transl. Med. 4(125), 125ra30 (2012).
101. Wong NC, Bhadri VA, Maksimovic J et al. Stability of gene expression and epigenetic profles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics 15, 416 (2014).
102. Torphy RJ, Tignanelli CJ, Kamande JW et al. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLoS ONE 9(2), e89474 (2014).
103. Boj SF, Hwang CI, Baker LA et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160(1-2), 324-338 (2015).